From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

 
• By Alaric DeArment
  
3d illustration of T cells attacking a cancer cell
In its third quarter earnings, Poseida said it would wind down its autologous CAR-T for myeloma and refocus on off-the-shelf therapy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas